Every 10-Q that Seer, Inc. (SEER) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow SEER and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SEER filings page.
Seer, Inc. reported continued operating losses while tightening expenses in the quarter ended June 30, 2026. Total revenue was $3.1 million, down 23% from $4.1 million a year earlier, driven by lower product and service sales and the absence of related-party revenue. For the first six months, revenue was $5.9 million, down 29% year over year.
Cost controls were significant: research and development expense fell 27% to $17.0 million for the first half and selling, general and administrative expense fell 11% to $19.6 million. As a result, the net loss narrowed to $33.7 million for the first six months of 2026 from $39.4 million in 2025, and operating cash outflow was $25.0 million versus $26.1 million.
Liquidity remains a key strength. As of June 30, 2026, Seer held $209.5 million in cash, cash equivalents and investments and reported no debt, and management believes this will fund operations for at least 12 months. The company also continued a share repurchase program, buying 1.7 million shares for $3.0 million in the first half. Seer is investing in its Proteograph Product Suite while absorbing $3.8 million of losses from its equity investment in PrognomiQ.
Seer, Inc. reported Q1 2026 revenue of $2.8M, down from $4.2M a year earlier as both product and service sales declined. Gross profit fell to $1.0M from $2.1M.
The company posted a net loss of $16.8M for the quarter, an improvement from a $19.9M loss in Q1 2025, helped by lower research and development and selling, general and administrative expenses, including reduced stock-based compensation.
Seer ended March 31, 2026 with $219.5M in cash, cash equivalents and investments and an accumulated deficit of $482.8M. Operating cash outflow was $15.4M. The company repurchased about 1.46M Class A shares for $2.6M and believes its current liquidity can fund operations for at least twelve months.
Seer, Inc. (SEER) filed its Q3 2025 report, showing steady revenue and narrowed losses. Total revenue was $4.1 million with gross profit of $2.1 million. Operating expenses fell to $21.5 million from $26.3 million a year ago, reducing the quarterly net loss to $18.2 million from $21.3 million. For the first nine months, revenue reached $12.4 million (up 22% year over year) and net loss improved to $57.6 million.
Cash, cash equivalents and investments totaled $251.2 million as of September 30, 2025, and operating cash use was $33.6 million year to date. The company repurchased 1,006,400 shares in Q3 for $2.0 million and 5,232,886 shares year to date for $10.1 million, with $3.1 million remaining under authorization. International sales represented 48% of Q3 revenue, and two customers accounted for 15% and 10% of quarterly revenue.
The company highlighted its May launch of the Proteograph ONE Assay and SP200 instrument. Class B common stock will automatically convert into Class A on December 9, 2025.